TD Asset Management’s Fate Therapeutics FATE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-25,000
Closed -$184K 1383
2024
Q1
$184K Buy
+25,000
New +$155K ﹤0.01% 1360
2023
Q4
Sell
-141,652
Closed -$300K 1414
2023
Q3
$300K Buy
141,652
+70,826
+100% +$235K ﹤0.01% 1340
2023
Q2
$337K Hold
70,826
﹤0.01% 1323
2023
Q1
$404K Hold
70,826
﹤0.01% 1304
2022
Q4
$715K Sell
70,826
-18,700
-21% -$351K ﹤0.01% 1208
2022
Q3
$2M Sell
89,526
-22,714
-20% -$656K ﹤0.01% 1002
2022
Q2
$2.78M Sell
112,240
-5,340
-5% -$147K ﹤0.01% 908
2022
Q1
$4.56M Buy
117,580
+10,899
+10% +$422K ﹤0.01% 843
2021
Q4
$6.24M Hold
106,681
0.01% 807
2021
Q3
$6.32M Buy
106,681
+18,871
+21% +$1.48M 0.01% 764
2021
Q2
$7.27M Sell
87,810
-800
-0.9% -$64.5K 0.01% 738
2021
Q1
$7.31M Sell
88,610
-570
-0.6% -$54.6K 0.01% 724
2020
Q4
$8.11M Buy
89,180
+30,700
+52% +$1.91M 0.01% 652
2020
Q3
$2.34M Buy
58,480
+24,100
+70% +$841K ﹤0.01% 870
2020
Q2
$1.18M Buy
34,380
+3,271
+11% +$97.5K ﹤0.01% 1017
2020
Q1
$691K Sell
31,109
-3,900
-11% -$98.6K ﹤0.01% 1100
2019
Q4
$685K Sell
35,009
-7,100
-17% -$113K ﹤0.01% 1186
2019
Q3
$654K Buy
42,109
+200
+0.5% +$3.83K ﹤0.01% 1137
2019
Q2
$851K Buy
41,909
+1,700
+4% +$30.6K ﹤0.01% 1079
2019
Q1
$706K Sell
40,209
-4,000
-9% -$63.1K ﹤0.01% 1107
2018
Q4
$567K Buy
44,209
+3,024
+7% +$42.2K ﹤0.01% 1195
2018
Q3
$671K Buy
41,185
+5,785
+16% +$68.4K ﹤0.01% 1235
2018
Q2
$401K Sell
35,400
-6,200
-15% -$68.3K ﹤0.01% 1308
2018
Q1
$406K Buy
41,600
+22,932
+123% +$220K ﹤0.01% 1237
2017
Q4
$114K Buy
+18,668
New +$83.3K ﹤0.01% 1322

Other funds holding FATE